VIDEO: Two new brain tumor therapies on the horizon

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

As I mentioned earlier, this year, there's likely to be two approvals of novel therapies for brain tumors. The IDH-inhibitor vorasidenib for low-grade gliomas will represent the first advancing of treatment of these tumors since 1999 when temozolomide, the standard chemotherapy, was introduced. And tovorafenib, small-molecule inhibitor that targets RAF, will also represent a major advance in an area that until recently has had very little effective treatment. So, I think these targeted therapies have really represented the major advances, but there are also multiple other areas that have shown encouraging results, although these have not yet led to regulatory approval.